Prospective study of adding camrelizumab and radiotherapy to nab-paclitaxel and gemcitabine for locally advanced pancreatic adenocarcinoma

Chemotherapy alone for locally advanced pancreatic adenocarcinoma (LAPC) has limited efficacy. A prospective cohort study at Sun Yat-sen University (Guangzhou, China) evaluated addition of camrelizumab plus radiotherapy to nab-paclitaxel plus gemcitabine chemotherapy. Compared with chemotherapy alone, combination treatment resulted in significant improvement of progression-free and overall survival.